Skip to Main Content

Katy K. Tsai


Oncologist and melanoma specialist

Dr. Katy K. Tsai is a medical oncologist who specializes in treating melanoma and other skin cancers.

In addition to caring for patients, Tsai conducts clinical trials with two of her colleagues in cutaneous oncology, Dr. Adil Daud and Dr. Alain Algazi, seeking new and better therapies for patients with advanced melanoma or head and neck cancers. She also has a long-standing research interest in quality of life and outcomes for patients receiving immunotherapy.

Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown. She completed a residency in internal medicine at the University of North Carolina at Chapel Hill, followed by a fellowship in medical oncology at UCSF, where she served as chief fellow.

Tsai is a member of the American Society of Clinical Oncology. She was born in Taiwan and raised in Toronto.

  • Education

    Brown University School of Medicine, 2010

  • Residencies

    University of North Carolina School of Medicine, Internal Medicine, 2013

  • Fellowships

    UCSF, Medical Oncology, 2015

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Assistant Professor

Where I see patients (2)

    My reviews


    Overall Experience
    175 Ratings
    Explained things in a way that was easy to understand
    174 Ratings
    Did the doctor pay attention to your concerns
    173 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    171 Ratings
    Knew the important information about your medical history
    173 Ratings
    The provider showed respect for what you had to say
    171 Ratings
    The provider spent enough time with me
    172 Ratings
    Decorative Caduceus

    A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignanci...

    Assess the safety and tolerability of single-agent RP1 in solid organ transplant patients with cutaneous malignancies by incidence of subjects with treatment-emergent adverse events


    Decorative Caduceus

    Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

    Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the ...


    Decorative Caduceus

    Safety of ABM-1310 in Patients With Advanced Solid Tumors


    Decorative Caduceus

    Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

    Percentage of subjects with adverse events (AEs)


    Decorative Caduceus

    A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without ...

    DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with binimetinib. The number of DLTs will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study


    Decorative Caduceus

    CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NS...

    Assess dose limiting toxicity as defined in the protocol